

### FY 2006 Key Figures

- ❖ Sales ↑ **112%**
- ❖ EBITDA ↑ **123.5%**
- ❖ Operating net profit after tax & minorities ↑ **83.4%**
- ❖ Net profit after tax & minorities ↑ **669.1%**

### P&L HIGHLIGHTS & RATIOS

		FY 2005	FY 2006
SALES	(000 €)	142,498	301,840
EBITDA	(000 €)	27,539	61,555
EAT	(000 €)	12,620	* 23,147
EPS	(€)	0.35	0.64
P/E	(x)	59.39	32.38
P/BV	(x)	11.16	3.66
P/SALES	(x)	5.26	2.48
ROE	(%)	18.8%	11.3%

Financial ratios calculated with year end number of shares (36,000,000) and at share price € 20.82 (09/02/2007).

\*Operating figures excluding extraordinary profits of € 73.9 mil. from Lamda Detergent placement.

### Key Developments

- ❖ FY 2006 business plan assumptions, which were more than double in comparison to FY 2005, have been successfully accomplished. EBITDA amounted to 61,6 mil.€, while EBITDA margin stood at 20%.
- ❖ In 2006 Neochimiki managed to acquire 5 new production plants (4 chemical plants and 1 detergent plant), 2 logistic centers and private own port facilities in Avlida. After the completion of the recent investments, Neochimiki has reached a dominant position in the Greek market thus playing an active role in the on going process of consolidation in the sector.

### Outlook

- ❖ Following the decision of Lamda's BoD to merge with EBIK, VETERIN, ELPHARMA, Neochimiki will no longer be able to consolidate Lamda Detergent going forward as it will only own 12,7% of the new entity, ALapis. Therefore, Neochimiki intends to place up to 34% of Lamda Detergent. The placement proceeds will be used for the financing of the further expansion in to Southeastern Europe.
- ❖ Furthermore Neochimiki intends to restructure its current debt by issuing a convertible bond of up to € 100 mil. and will propose this to its shareholders' meeting, which is to be held in the near future.
- ❖ Following the successful completion of the placement and the convertible bond issue, Neochimiki will have significantly strengthened its equity in order to continue the company's strategy of achieving high growth rates in the coming years.

### Consolidated Financial Results

(FY: December) (000 €)	FY 2004	FY 2005	FY 2006
Sales	82,905	142,498	301,840
Cost of Goods Sold	-56,233	-99,623	-215,439
Gross Profit	26,672	42,875	86,401
Other Revenues-(Expenses)	777	711	664
SG&A Expenses	-15,007	-23,027	-39,668
EBITDA	18,084	27,539	61,555
Depreciation	-5,641	-6,980	-14,158
EBIT	12,443	20,559	47,397
Total Financial Results	-3,980	-5,546	63,872
EBT	8,463	15,013	111,269
Taxation	-987	-2,355	-7,952
Minorities	150	39	6,256
EAT & Minorities	7,326	12,620	97,061

### Financial Calendar

Q1 2007	10/05/07
AGM	29/06/07
Ex - Dividend	03/07/07
Dividend Payment	11/07/07
6M 2007	26/07/07
9M 2007	08/11/07

## Consolidated Income Statement

(FY: December) (M €)	FY 2004	Q1 2005	Q2 2005	Q3 2005	Q4 2005	FY 2005	Q1 2006	Q2 2006	Q3 2006	Q4 2006	FY 2006
Sales	82.9	24.5	31.3	38.0	48.7	142.5	41.5	65.2	76.5	118.6	301.8
Cost of Goods Sold	-56.2	-16.3	-22.7	-27.4	-33.2	-99.6	-27.9	-49.4	-55.0	-83.1	-215.4
Gross Profit	26.7	8.2	8.6	10.6	15.5	42.9	13.6	15.8	21.5	35.5	86.4
Other Revenues-(Expenses)	0.8	0.1	0.1	0.1	0.4	0.7	0.2	0.3	3.9	-3.8	0.7
SG&A Expenses	-15.0	-4.0	-4.0	-5.2	-9.8	-23.0	-6.3	-7.5	-11.7	-14.2	-39.7
EBITDA	18.1	5.9	6.5	7.2	7.9	27.5	10.2	11.4	16.7	23.3	61.6
Depreciation	-5.6	-1.6	-1.9	-1.7	-1.8	-7.0	-2.7	-2.7	-3.0	-5.8	-14.2
EBIT	12.4	4.3	4.6	5.5	6.1	20.6	7.6	8.7	13.7	17.5	47.4
Total Financial Results	-4.0	-1.2	-1.3	-1.5	-1.6	-5.5	47.0	-2.2	-3.0	22.1	63.9
EBT	8.5	3.1	3.3	4.1	4.5	15.0	54.5	6.5	10.7	39.6	111.3
Taxation	-1.0	-0.5	-0.4	-0.9	-0.6	-2.4	-1.1	-0.8	-2.3	-3.6	-8.0
Minorities	0.2	0.0	0.0	0.0	0.1	0.0	0.2	1.3	2.3	2.5	6.3
EAT & Minorities	7.3	2.7	2.9	3.2	3.8	12.6	53.2	4.3	6.1	33.4	97.1

Margin Analysis %	FY 2004	Q1 2005	Q2 2005	Q3 2005	Q4 2005	FY 2005	Q1 2006	Q2 2006	Q3 2006	Q4 2006	FY 2006
Gross Profit	32.2%	33.3%	27.4%	28.0%	31.8%	30.1%	32.9%	24.2%	28.1%	29.9%	28.6%
SG&A Expenses	18.1%	16.3%	12.9%	13.8%	20.1%	16.2%	15.2%	11.5%	15.2%	12.0%	13.1%
EBITDA	21.8%	24.1%	20.8%	19.0%	16.2%	19.3%	24.6%	17.4%	21.8%	19.6%	20.4%
EBIT	15.0%	17.6%	14.7%	14.6%	12.6%	14.4%	18.2%	13.3%	17.9%	14.7%	15.7%
EBT	10.2%	12.9%	10.4%	10.7%	9.3%	10.5%	131.4%	9.9%	13.9%	33.4%	36.9%
EAT & Minorities	8.8%	10.9%	9.4%	8.3%	7.9%	8.9%	128.1%	6.6%	8.0%	28.2%	32.2%


Period / Period %	FY 2004	Q1 2005	Q2 2005	Q3 2005	Q4 2005	FY 2005	Q1 2006	Q2 2006	Q3 2006	Q4 2006	FY 2006
Sales	48.1%	57.4%	75.8%	95.9%	71.9%	69.6%	108.4%	101.2%	143.6%	111.8%	
Gross Profit	53.8%	31.3%	67.9%	82.3%	60.7%	67.1%	84.5%	101.9%	128.8%	101.5%	
SG&A Expenses	59.2%	14.9%	60.1%	70.7%	53.4%	58.7%	85.5%	122.4%	45.4%	72.3%	
EBITDA	44.1%	44.4%	59.1%	59.9%	52.3%	73.6%	74.5%	130.6%	194.8%	123.5%	
EBIT	49.4%	49.3%	72.1%	87.2%	65.2%	75.5%	89.1%	147.0%	185.3%	130.5%	
EBT	54.6%	56.4%	67.2%	137.5%	77.4%	1632.8%	98.5%	163.2%	771.3%	641.2%	
EAT & Minorities	57.3%	53.2%	56.7%	127.7%	72.3%	1891.7%	46.9%	92.5%	770.9%	669.1%	

## Consolidated Balance Sheet


(in 000. €)

	FY 2004	FY 2005	FY 2006
<b>ASSETS</b>			
<b>Non-current Assets</b>			
Property, plant and equipment	107,407	164,584	346,275
Intangible Assets	5,956	11,234	16,529
Other long-term receivables	116	178	219
Deferred taxes	644	431	1,152
<b>Total Non-Current Assets</b>	<b>114,123</b>	<b>176,427</b>	<b>364,175</b>
<b>Current Assets</b>			
Inventories	19,135	36,672	50,385
Trade and other receivables	21,449	24,298	73,498
Financial assets at fair value through profit and loss	0	74	0
Cash and Cash equivalents	1,849	4,813	22,041
<b>Total Current Assets</b>	<b>42,433</b>	<b>65,857</b>	<b>145,924</b>
<b>TOTAL ASSETS</b>	<b>156,556</b>	<b>242,284</b>	<b>510,099</b>
<b>EQUITY &amp; LIABILITIES</b>			
<b>Capital &amp; Reserves</b>			
Share Capital	10,800	10,800	10,800
Share premium	5,677	5,677	5,677
Escalation differences & other reserves	35,022	44,511	142,337
Retained earnings	2,579	2,066	2,175
Minority Rights	274	4,131	33,794
<b>Total Equity</b>	<b>54,352</b>	<b>67,185</b>	<b>194,783</b>
<b>Long-term Liabilities</b>			
Loans	62,202	120,083	164,500
Deferred taxes	1,674	3,618	5,049
Personnel dismissal and retirement compensation provision	122	137	1,873
Other long-term liabilities	50	29	48
<b>Total Long-term Liabilities</b>	<b>64,048</b>	<b>123,867</b>	<b>171,470</b>
<b>Short-term Liabilities</b>			
Trade accounts payable & other liabilities	12,614	38,263	46,629
Short-term borrowings	23,114	9,184	79,672
Income taxes payable	2,427	3,785	5,978
Other Liabilities	0	0	11,567
<b>Total Short-term Liabilities</b>	<b>38,155</b>	<b>51,232</b>	<b>143,846</b>
<b>TOTAL EQUITY &amp; LIABILITIES</b>	<b>156,556</b>	<b>242,284</b>	<b>510,099</b>


## EPS



## ROE



## ROIC



This presentation contain forward-looking statements. These forward-looking statements are based upon current expectations and assumptions regarding anticipated developments and other factors affecting the Group. They are not historical facts, nor are they guarantees of future performance. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements. Further details of potential risks and uncertainties affecting NEOCHIMIKI Group are described in the NEOCHIMIKI's filings with the Athens Stock Exchange. These forward-looking statements speak only as of the date of this presentation.